 this is a follow - up to the question we asked on the last call. 
 we want to know what you think about the prospects for the atopic derm market with the launch of atogepant and atopic dermatitis with the launch of atogepant in the second half of the year and the launch of atopic dermatitis with the launch of atopic dermatitis in the second half of the year with the launch of atogepant into the second half of the year. 
 we also want to know what you think about the prospects of the prophylaxis market with the launch of prophylaxis in the second half of the year. 
 can you give us some sort of a feel for the timeline for that to happen or is this still likely possibility or is this, at this point, just a lot less likely? 
 we think that the drug pricing environment in DC is still very fluid, and there are a number of proposals on the table or a number of proposals that are being discussed, and there is a fairly wide range there. So we would not see a change in the pricing dynamic after the HUMIRA biosimilar event. we would support proposals that would lower those, make